Slow Going With CAR T-Cell Therapy for Solid Tumors

(MedPage Today) -- Almost 4 years after the first chimeric antigen receptor (CAR) T-cell therapies received FDA approval, the transformative impact of the treatment on refractory hematologic malignancies has yet to translate into the field of solid...